Sign In
Buy MRTX
$58.70
+0 (+0%)
At Close: Apr 19, 2024
iRobot, Fox Factory, TripAdvisor And Some Other Big Gainers From Friday
09:13am, Monday, 08'th Aug 2022 Benzinga
U.S. stocks closed mixed on Friday following the release of jobs data for July. Here is the list of some big stocks moving higher in the previous session.
Carvana Co. (NYSE: CVNA) jumped 40.1% to clo
Why Quoin Pharmaceuticals Plunged Over 62%; Here Are 120 Biggest Movers From Friday
07:05am, Monday, 08'th Aug 2022 Benzinga
Gainers
Cooper-Standard Holdings Inc. (NYSE: CPS) jumped 69.6% to close at $8.53 on Friday following better-than-expected Q2 results.
Intelligent Living Application Group Inc. (NASDAQ: ILAG) surged 6
Coinbase, MercadoLibre And Some Other Big Stocks Recording Gains On Thursday
08:00am, Friday, 05'th Aug 2022 Benzinga
U.S. stocks closed mixed on Thursday following the release of weekly jobless claims data. Here is the list of some big stocks moving higher in the previous session.
ChemoCentryx, Inc. (NASDAQ: CCXI)
Mirati (MRTX) Q2 Loss Narrower Than Expected, Sales Beat
05:17pm, Thursday, 04'th Aug 2022 Zacks Investment Research
Mirati Therapeutics' (MRTX) Q2 earnings and sales beat the mark. The company plans to start early-stage clinical studies for a SOS1 inhibitor by year-end.
Mirati (MRTX) Q2 Loss Narrower Than Expected, Sales Beat
02:18pm, Thursday, 04'th Aug 2022
Mirati Therapeutics' (MRTX) Q2 earnings and sales beat the mark. The company plans to start early-stage clinical studies for a SOS1 inhibitor by year-end.
Mirati (MRTX) Reports Q2 Loss, Tops Revenue Estimates
10:15pm, Wednesday, 03'rd Aug 2022 Zacks Investment Research
Mirati (MRTX) delivered earnings and revenue surprises of 9.92% and 143.73%, respectively, for the quarter ended June 2022. Do the numbers hold clues to what lies ahead for the stock?
Mirati Therapeutics, Inc. (MRTX) CEO David Meek on Q2 2022 Results - Earnings Call Transcript
10:11pm, Wednesday, 03'rd Aug 2022
Mirati Therapeutics, Inc. (NASDAQ:MRTX ) Q2 2022 Earnings Conference Call August 3, 2022 4:30 PM ET Company Participants Ryan Asay - Vice President of Corporate Affairs David Meek - Chief Executive Of
Mirati Therapeutics to Report Second Quarter 2022 Financial Results and Recent Corporate Updates
04:30pm, Wednesday, 20'th Jul 2022
SAN DIEGO , July 20, 2022 /PRNewswire/ -- Mirati Therapeutics, Inc. (NASDAQ: MRTX), a clinical-stage targeted oncology company, will announce financial results for the second quarter of 2022 along wit
Biotech ETF Tops in June: 5 Stocks That Outperform
05:08pm, Thursday, 30'th Jun 2022 Zacks Investment Research
Virtus LifeSci Biotech Clinical Trials ETF (BBC) topped the list of the best-performing U.S. equity ETFs in June, gaining about 10%. The rally was driven by traders' "short squeeze" and investors' bar
Biotech ETF Tops in June: 5 Stocks That Outperform
02:52pm, Thursday, 30'th Jun 2022
Virtus LifeSci Biotech Clinical Trials ETF (BBC) topped the list of the best-performing U.S. equity ETFs in June, gaining about 10%. The rally was driven by traders' "short squeeze" and investors' bar
What's Next For Mirati Therapeutics Stock After A 20% Rise In A Month?
10:00am, Wednesday, 29'th Jun 2022
Mirati Therapeutics stock (NASDAQ: MRTX) has risen a solid 20% in a month, outperforming the broader markets with the S&P500 down 6%.
Mirati Therapeutics: Growth Cycle Transition
02:46am, Friday, 24'th Jun 2022
After the most aggressive growth phase, you can continue to make substantially more, if and only if, the drug later becomes a blockbuster in commercialization. After years of innovation, Mirati Therap
Mirati: Not Looking Good In 2022, But Stronger Prospects In 2-3 Years
05:10pm, Tuesday, 21'st Jun 2022
Mirati will probably not get accelerated approval for adagrasib in 2nd line NSCLC. This will delay their program for two years.
Seven reasons the beleaguered biotech sector is now a 'buy'
11:33am, Saturday, 18'th Jun 2022 MarketWatch
Investors ought to take advantage of low prices for a long-term view.
Why Mirati Therapeutics Stock Is Skyrocketing This Week
08:40pm, Thursday, 09'th Jun 2022 The Motley Fool
The company presented great data at the American Society of Clinical Oncology annual meeting.
